Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Mangalam Drugs & Organics Ltd. ( (IN:MANGALAM) ) is now available.
Mangalam Drugs & Organics Ltd. has announced that its Board of Directors, at a meeting held on 15 January 2026, approved the company’s unaudited standalone and consolidated financial results for the quarter ended 15 January 2026, with the statutory auditors issuing reports free of modified opinions. The board also accepted the resignation of Chief Financial Officer Ajay Avinash Samant, effective 31 January 2026, and took note of the resignation of Company Secretary and Compliance Officer Anuradha Pandey, signalling an imminent reshuffle in key financial and compliance leadership roles that could be closely watched by investors and regulators.
More about Mangalam Drugs & Organics Ltd.
Mangalam Drugs & Organics Ltd., based in Mumbai with manufacturing facilities in Vapi, Gujarat, operates in the pharmaceuticals and chemicals sector, focusing on the production of active pharmaceutical ingredients and related organic intermediates for domestic and export markets.
Average Trading Volume: 49,986
Technical Sentiment Signal: Sell
Current Market Cap: 710.1M INR
For a thorough assessment of MANGALAM stock, go to TipRanks’ Stock Analysis page.